All News Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

End-of-day quote Nasdaq Other stock markets 03:30:00 12/06/2024 am IST			5-day change	1st Jan Change
25.16 ^USD	+5.01%		+11.57%	+141.92%

12/06	Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy	MT
12/06	Dianthus Therapeutics Gets FDA Clearance for DNTH103 Phase 2 Trial	DJ

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy	12/06	MT
Dianthus Therapeutics Gets FDA Clearance for DNTH103 Phase 2 Trial	12/06	DJ
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)	12/06	AQ
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference	31/05	AQ
HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target	16/05	MT
Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating	10/05	MT
Dianthus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results	10/05	AQ
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference	09/05	AQ
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/05	AQ
Lei Meng Announces Not to Stand for Reelection as Director of Dianthus Therapeutics, Inc	12/04	CI
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting	11/04	AQ
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/04	AQ
Wedbush Raises Dianthus Therapeutics' PT to $33 From $24, Says Q4 2023 Results As-Expected, Keeps Outperform Rating	22/03	MT
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results	22/03	AQ
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	08/03	AQ
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)	26/02	AQ
Dianthus Therapeutics, Inc. Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis	26/02	CI
Stifel Initiates Dianthus Therapeutics With Buy Rating, $44 Price Target	15/02	MT
Wedbush Lifts Dianthus Therapeutics' PT to $24 From $23, Updates Estimates Following Private Placement; Keeps Outperform Rating	26/01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

All News

Filters